Investor Quick Links
Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.
About Aspira Women's Health
Our Mission
Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products Ova1® and Overa® detect the risk of ovarian malignancy in women with adnexal masses. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
Most Recent Press Releases
Aspira Women’s Health Regains Nasdaq Compliance
September 13, 2023 08:00 ET AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that it received written notice from the Nasdaq Stock Market LLC (“NASDAQ”) on September 12, 2023 informing the Company…
Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer
September 11, 2023 08:00 ET AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer. Dr. Ryan Phan, who stepped down…